SOX2 and cholangiocarcinoma: In addition, SOX2 was highly expressed in breast invasive carcinoma (BRCA), cholangiocarcinoma, colon adenocarcinoma (COAD), kidney chromophobe, liver hepatocellular carcinoma (LIHC), lung squamous cell carcinoma (LUSC), and uterine corpus endometrial carcinoma (UCEC), whereas its expression levels were low in kidney renal clear cell carcinoma (KIRC) and stomach adenocarcinoma (STAD) (Figure 1D).